Molecular characterisation of the NDM-1-encoding plasmid p2189-NDM in an Escherichia coli ST410 clinical isolate from Ghana

PLoS One. 2018 Dec 21;13(12):e0209623. doi: 10.1371/journal.pone.0209623. eCollection 2018.

Abstract

Global dissemination of New Delhi metallo-β-lactamase (NDM)-producing bacteria has become a major health threat. However, there are few reports regarding the identification and characterisation of NDM-producing bacteria from West Africa, including Ghana. An Escherichia coli strain with resistance to meropenem was isolated from the Tamale Teaching Hospital in Ghana. Its identification and determination of antibiotic susceptibility profile were carried out using commercial systems. The antibiotic resistance mechanism was analysed by phenotypic detection kits, PCR, and DNA sequencing. Conjugation experiments, S1 nuclease pulsed field gel electrophoresis, and Southern blotting were performed. Finally, the NDM-1-harbouring plasmid was characterised using next-generation sequencing and phylogenetic analysis. The meropenem-resistant Escherichia coli strain EC2189 harboured blaNDM-1 and belonged to sequence type 410. blaNDM-1 was located on the IncHI type transferrable plasmid p2189-NDM (248,807 bp long), which co-carried multiple resistance genes, such as blaCTX-M-15, aadA1, aac(6')-Ib, sul3, dfrA12, and cmlA1. p2189-NDM phylogenetically differed from previously identified blaNDM-1-positive IncHI type plasmids. A truncated Tn125 containing blaNDM-1 was bracketed by an ISSm-1-like insertion sequence upstream and by a site-specific integrase downstream. To the best of our knowledge, we have, for the first time identified and molecularly characterised an NDM-1-producing Enterobacteriaceae strain in Ghana with blaNDM-1 that had a novel genetic structure. Our findings indicate a possibility of NDM-1 dissemination in Ghana and underscore the need for constant monitoring of carbapenemase-producing bacteria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Drug Resistance, Multiple, Bacterial / genetics
  • Enterobacteriaceae Infections / drug therapy
  • Enterobacteriaceae Infections / genetics*
  • Enterobacteriaceae Infections / microbiology
  • Escherichia coli / drug effects
  • Escherichia coli / genetics*
  • Escherichia coli / pathogenicity
  • Humans
  • Microbial Sensitivity Tests
  • Multilocus Sequence Typing
  • Phylogeny
  • Plasmids / genetics*
  • beta-Lactamases / genetics*

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases
  • beta-lactamase NDM-1

Grants and funding

This study was supported by the Japan Agency for Medical Research and Development (AMED, URL: http://www.amed.go.jp/en/) under Grant Number 17fm0108010h0003 (MO, TS, SI, RS). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.